• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » An Opioid Combo Falls Short in Depression

An Opioid Combo Falls Short in Depression

February 1, 2019
Chris Aiken, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Chris Aiken, MDChris Aiken, MD. 
Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Opioids have a bad name these days. But let’s not forget that they were once consid­ered a first-line treatment for depression before the discovery of MAOIs and tricy­clics in the 1950s. That history has been revived recently by buprenorphine, a par­tial opioid agonist that was fast-tracked by the FDA for treatment-resistant depression. Buprenorphine showed promise in early studies, where it reduced both depression and suicidality. The effect was rapid, much like we see with ketamine, which may also work through the opioid system (see Re­search Update in TCPR, Jan 2019).

In the end, the FDA handed this novel therapy a thumbs down. The issue was not safety but efficacy, although there were also concerns that short-term trials might not be adequate to assess the addictive liability of buprenorphine.

The manufacturer submitted 4 trials, but only 2 of those trials had positive results, and there were sev­eral flaws in the data. The company switched the primary outcome mea­sures after their initial choices failed; they relied on averaged ratings from each time point instead of the final score; and they abbreviated the main rating scale, the MADRS, in ways that appeared to bias the results. Buprenorphine acts differently at high (8 mg) and low (2 mg) doses, but that did not appear to be the issue—neither dose worked well in these studies.

Buprenorphine remains available as Suboxone, which is FDA-approved for opioid dependence and became generic in June 2018. However, there is an important difference between Suboxone and its antidepressant cousin that failed to make it to market. Both drugs com­bine buprenorphine with an opioid antagonist to prevent abuse. Suboxone uses naloxone, a broad antagonist, while buprenorphine is paired with samidor­phan, which selectively antagonizes the mu-opioid receptors. Samidorphan is not currently available, but we may hear from it again. It is undergoing phase II studies as a combo pill with olanzapine in hopes that it will curb the weight gain on that antipsychotic.
General Psychiatry
KEYWORDS depression news_of_note
    Aiken eic 150x150
    Chris Aiken, MD

    The Antipsychotic-Stimulant Combo

    More from this author
    www.thecarlatreport.com
    Issue Date: February 1, 2019
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Dark and Light Therapy, TCPR, February 2019
    An Opioid Combo Falls Short in Depression
    Prazosin for Alcohol Use Disorders
    Does Mania Follow the Sun?
    CBT for Insomnia
    Light and Darkness in Bipolar Disorder
    Trintellix and Cognition: A Closer Look
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • canstockphoto6759394.jpg
      General Psychiatry

      Throwback Thursday: Brief Therapy for ADHD

      You started a stimulant medication for a young woman with ADHD. When she returns her symptoms are 70% better, but what can we do about the rest? Today a conversation with...

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.